ArticleScientific reports2026
Colorectal cancer cells respond differentially to autophagy induced by tyrosine kinase inhibitors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy plays an important role in the response of tumors to environmental stress including colorectal cancer (CRC). The present study aimed to investigate the relationship between the autophagic capacities of CRC cells and their sensitivities to Nintedanib and Regorafenib, two TKIs with clinical activity in metastatic CRC. Our results showed various effects of these two TKIs on cell viability across a panel consisting of 12 well-characterized CRC cell lines. We showed an opposite cytotoxicity profile between HT-29 and LoVo cell lines for both TKIs which is accompanied by an induction of autophagy in cell-type and drug-dependent manner. Interestingly, pharmacologic and genetic autophagy inhibition decreased the cytotoxic activity of Nintedanib but did not affect the activity of Regorafenib. In addition, signaling pathways analysis revealed opposing effects on the Akt-mTOR and Erk-signaling pathways by the two TKIs. Nintedanib inhibits the Akt- mTOR pathway which is compensated by activation of Erk signaling, whereas Regorafenib is a strong inhibitor of Erk-signaling and is accompanied by Akt- mTOR activation. Taken together, our results indicate that autophagy contributes to the cytotoxic activity of Nintedanib but not that of Regorafenib. These results highlighted that CRC with high autophagic flux may be selectively sensitive to Nintedanib.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.